Studies conducted in animal models, such as that of Buckley et al. (2014), have demonstrated that the inhibition of interleukin-6 (IL-6) and CRF1 receptors in vivo normalized stress-induced defecation (p < 0.01) and visceral pain sensitivity (p < 0.001) in an IBS rat model, indicating a potential therapeutic strategy [22]. The gene discussed is IL6; the disease is irritable bowel syndrome.